openPR Logo
Press release

Peyronie’s Disease Treatment Market 2019 | Explore Future Growth by 2026

06-05-2019 07:22 AM CET | Health & Medicine

Press release from: Coherent Market Insights (CMI)

Peyronie’s Disease

Peyronie’s Disease

The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product is estimated to generate USD 100 million in revenue for Peyronie’s disease by 2018. In Japan, BioSpecifics Technologies Corp. has granted Asahi Kasei Pharma the rights to develop and market XIAFLEX in Japan for Peyronie's disease. Further, the company is also partnering with global companies in Canada, Europe, Mexico, and Brazil for commercializing XIAFLEX for PD.

Get Free PDF Brochure of Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/61

With increasing awareness and research on this disease, new drug molecules could be made available in the market.

The exact cause of plaque formation is not known. Hence, treatment is done with the available research and knowledge of plaque formation. There are various treatment options followed for Peyronie’ disease basis on which the market is analyzed. These include drugs, surgery and devices. The drugs market can be analyzed based on the administration route i.e. oral and injectable. Drugs prescribe through oral route include Vitamin E, Potassium amino-benzoate ("Potaba"), Tamoxifen, Colchicine, and Carnitine. Similarly, the injectable drugs include Verapamil, Interferon, and Collagenase. Use of oral drugs is limited as none of the studies conducted so far for Peyroniee’s disease have shown positive results of these drugs over the placebo.

On the other hand injectables show some positive outcomes over placebo. However, more studies are required to establish the efficacy. Studies with collagenase have shown positive outcomes for its use in Peyronie's disease. Therefore, Xiaflex (Collagenase clostridium histolyticum) from BioSpecifics Technologies Corporation is the only FDA approved product indicated for Peyronie's disease in adult men. Approved in 2013, Xiaflex is marketed in the U.S. by Endo International plc. In Europe, Collagenase clostridium histolyticum is available by the brand name Xiapex.

Free Request Sample of Report: https://www.coherentmarketinsights.com/insight/request-sample/61

A penile prosthetic device is another good treatment option for Peyronie's disease and moderate-to-severe ED. This device helps straighten the penis. Surgical procedure on the other hand involves grafting the space being emptied on removal of the plaque.

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Us:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Peyronie’s Disease Treatment Market 2019 | Explore Future Growth by 2026 here

News-ID: 1764976 • Views:

More Releases from Coherent Market Insights (CMI)

Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2030 | Carestream Health, Accurate Imaging, Inc., Alliance HealthCare Services
Huge Growth in Mobile Imaging Services Market 2023 to see Future Opportunities 2 …
𝗢𝘃𝗲𝗿𝘃𝗶𝗲𝘄: Mobile imaging services are provided by trained professionals who are equipped with state-of-the-art imaging technology that can be transported and set up on location. The images obtained through mobile imaging services are then transmitted electronically to the patient's healthcare provider for analysis and diagnosis. Mobile imaging services are used in a variety of healthcare settings, including hospitals, clinics, nursing homes, and home health agencies. They are particularly useful for imaging patients
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | Ion Beam Applications, Provision Healthcare, Mevion Medical Systems
Huge Growth in Particle Therapy Market 2023 to see Future Opportunities 2030 | I …
Coherent Market Insight has published a new research report titled "Particle Therapy Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Toshiba Corporation, Carestream Health, General Electric Company
Digital Mobile X Ray Devices Market 2023 to see Future Opportunities 2030 | Tosh …
Coherent Market Insight has published a new research report titled "Digital Mobile X Ray Devices Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns,
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities 2030 | LI-COR Biosciences, Analytik Jena US, Azure Biosystems, Berthold Technologies GmbH & Co. KG
Huge Growth in Chemiluminescence Imaging Market 2023 to see Future Opportunities …
Coherent Market Insight has published a new research report titled "Chemiluminescence Imaging Market 2023 analysis by Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges and Investment Opportunities)", size, share, and outlook. This research offers strategic recommendations based on industry experts' consultations on market development, consumer demand, sales patterns, revenue forecasts, gross margins, and regional growth. It focuses on regional developments as well as market growth, pricing, sales patterns, revenue forecasts, and

All 5 Releases


More Releases for Peyronie

Peyronie Disease Treatment Market is Set to See Revolutionary Growth in Decade C …
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲- The Global Peyronie Disease Treatment Report offers a thorough overview of the market, including data on market size, share, and forecasts for the future. The total breakdown of data by manufacturers, regions, types, and applications, as well as market drivers, opportunities, and disadvantages, are shown in this report. The Global Peyronie Disease Treatment Market Report will examine the effects of COVID-19 on the sector. The Global Peyronie Disease
Peyronie’s Disease Treatment Market it is Creating Real Change in the Healthca …
Peyronie's disease (PD) is condition wherein the penis is curved or bent due to development of plaque or a fibrous scar tissue inside the penis. This condition can cause painful erections and the penis gets bent while it is erected. The bent is towards the side where plaque is being formed i.e. either downwards or upwards. The condition is identified by a major bend or pain. In a few people
Peyronie’s Disease Treatment Market Set to Encounter Paramount Growth
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market Growing Popularity and Emerging Trend by 2026
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
Peyronie’s Disease Market - Only FDA approved product
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product
With Xiaflex the only FDA approved product for this disease, Endo dominates the …
The market is dominated by a single player, Endo International plc who sells the only FDA approved Peyronie’s disease product. In May 2015, the American Urological Association presented the first ever treatment guidelines for Peyronie’s disease recommending the use of Xiaflex. Furthermore, the company is creating awareness through its “Ask About the Curve” campaign. Also, reimbursement from the U.S. insurance providers will boost the demand for this product. The product